SOMERVILLE, Mass.–(BUSINESS WIRE)–Genetix Biotherapeutics Inc., the commercial leader in genetic medicine for rare disease with a focus on hematology, today unveiled its rapid turnaround into a profitable commercial enterprise and announced strong 2026 commercial performance, a multibillion-dollar growth trajectory, and strategic priorities. The company shared the update in a presentation by CEO David Meek at the Jefferies Global Healthcare Conference in London, UK. Genetix has established a

Subscribe to Our Newsletter

We keep your data private and share your data only with third parties that make this service possible. See our Privacy Policy for more information.